- Home
- SABR vs ADCT Comparison
SABR vs ADCT Comparison
Compare SABR & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SABR | ADCT |
|---|---|---|
| Founded | 2006 | 2011 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 580.9M | 484.4M |
| IPO Year | 2014 | 2019 |
Fundamental Metrics
Financial Performance| Metric | SABR | ADCT |
|---|---|---|
| Price | $1.77 | $4.55 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $2.50 | ★ $7.75 |
| AVG Volume (30 Days) | ★ 5.0M | 741.8K |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 283.56 | 30.86 |
| EPS | ★ 1.34 | N/A |
| Revenue | ★ $3,866,956,000.00 | $81,357,000.00 |
| Revenue This Year | $7.15 | N/A |
| Revenue Next Year | $3.40 | $66.49 |
| P/E Ratio | $1.31 | ★ N/A |
| Revenue Growth | 7.46 | ★ 14.85 |
| 52 Week Low | $0.81 | $1.20 |
| 52 Week High | $3.46 | $4.98 |
Technical Indicators
Market Signals| Indicator | SABR | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | 64.74 | 67.39 |
| Support Level | $1.72 | $3.28 |
| Resistance Level | $1.98 | $4.77 |
| Average True Range (ATR) | 0.11 | 0.27 |
| MACD | 0.03 | 0.08 |
| Stochastic Oscillator | 90.11 | 78.31 |
Price Performance
Historical ComparisonAbout SABR Sabre Corporation
Sabre holds the number-two air booking volume share in the global distribution system industry. The distribution segment represented 80% of total 2025 revenue and airline IT solutions 20% of revenue. The company sold its growing hotel IT solutions division to TPG in 2025 for $960 million in net proceeds. Transaction fees, which are mostly tied to volume and not price, account for the bulk of sales and profits.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).